idecabtagene vicleucel
2seventy bio,bms
['ide-cel']
oral session: outcomes after ide-cel in #rrmm with prior bcma therapy bcma-tt prior to car t has lower rr and pfs worse efficacy if bcma&lt;6m prior to car doris hansen #usmyelomacartconsortium #medtwitter #ash22 
Assistant Professor Hematology/BMT @Muschollings Plasma cell disorders/ BMT/Cellular Therapy. Opinions are my own and not employer’s